Pirtobrutinib is a non covalent inhibitor targeting BTK, with a therapeutic focus on specific B-cell malignancies, mainly covering two indications: relapsed refractory mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma treated with multi line therapy.

1. Recurrent or refractory mantle cell lymphoma (MCL)

(1) Applicable conditions: Adult patients must have received at least two systemic treatment regimens in the past, which must include a history of BTK inhibitor therapy.

(2) Clinical positioning: It can still exert therapeutic effects on traditional BTK inhibitor resistant patients and provide key treatment options for disease progression.

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

(1) Treatment prerequisite: Suitable for adult patients who have received at least two types of systemic therapy in the past, and the treatment plan must include both BTK inhibitors and BCL-2 inhibitors.

(2) Mechanism advantage: Overcoming the resistance mutation of covalent BTK inhibitors through non covalent binding, prolonging the response time to posterior line therapy.